← 返回首页
美国 · 平台与数据 · Benzinga

FDA Clears Teva's Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder

来源:Benzinga · 美国 40 分钟前
FDA Clears Teva's Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder
Benzinga

详细摘要

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced on Monday that the U.S. Food and Drug Administration (FDA) approved IGALMI (dexmedetomidine) sublingual film for at-home…

在 Benzinga 阅读全文 登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.benzinga.com)

推荐阅读